NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,312.54 mln
Float164 mln
Earnings Date08/05/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.28
Manipulation likely
1-Year Forecast
93.23
Transformational upside
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
4.15
Highly leveraged
ROE
-60.42
Deeply negative
Business Description
Ionis Pharmaceuticals is a California-based biotech company that develops and sells medicines targeting RNA, a key molecule that carries genetic instructions within the body. The company has several approved treatments on the market for serious conditions including spinal muscular atrophy, hereditary nerve disease, and rare disorders affecting fat metabolism. Ionis also has a broad pipeline of experimental therapies in clinical trials targeting heart disease, liver disease, neurological conditions, and other rare genetic illnesses. To support its research and commercialization efforts, the company works alongside major pharmaceutical partners including GSK, AstraZeneca, Novartis, Roche, and Biogen.